REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

3D Medicines Inc. (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: 3D Medicines Inc. Profile Updated: July 04, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

3D Medicines Inc is engaged in the research and development and commercialization of biopharmaceuticals. The company's main product is a subcutaneously-injectable PD-L1 antibody. The company was established in 2018 and is headquartered in Hong Kong, China.

Headquarters
Building 11, 118 Furong Hua Road, Pudong New District
Shanghai; Shanghai;

Contact Details: Purchase the 3D Medicines Inc. report to view the information.

Website: http://www.3d-medicines.com

Basic Information
Total Employees:
Purchase the 3D Medicines Inc. report to view the information.
Outstanding Shares:
Purchase the 3D Medicines Inc. report to view the information.
Registered Capital:
Purchase the 3D Medicines Inc. report to view the information.
Financial Auditors:
Purchase the 3D Medicines Inc. report to view the information.
Incorporation Date:
January 30, 2018
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
14.08%
Purchase this report to view the information.
9.02%
Purchase this report to view the information.
7.49%
Purchase this report to view the information.
5.4%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after 3D Medicines Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-41.45%▼
Total operating revenue
-41.91%▼
Operating profit (EBIT)
39.31%▲
EBITDA
42.23%▲
Net Profit (Loss) for the Period
40.03%▲
Total assets
-6.14%▼
Total equity
-6.05%▼
Operating Profit Margin (ROS)
-2.12%▼
Net Profit Margin
-1.31%▼
Return on Equity (ROE)
8.36%▲
Debt to Equity Ratio
0.39%▲
Quick Ratio
-0.09%▼
Cash Ratio
-0.16%▼

Similar companies

Sinopharm Group Company Limited
 
Shanghai Pharmaceuticals Holding Co.,Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
 
Nanjing Pharmaceutical Company Limited
Chongqing Zhifei Biological Products Co.,Ltd.
 
Hubei Biocause Pharmaceutical Co.,Ltd.
Shandong Boan Biotechnology Company Limited (Heze) (山东博安生物技术股份有限公司 (菏泽))
 
Shaanxi Kanghui Pharmaceutical Co., Ltd
Beijing Science Sun Pharmaceutical Co.,Ltd.
 
Zhongzhu Healthcare Holding Co.,Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd
 

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo